Genotype and allele frequencies of ABCB1 and SLCO1B1 polymorphisms in THAI HIV-infected patients
Keywords:
ABCB1, SLCO1B1, polymorphisms, Thai HIV-infected patientsAbstract
Background : Genetic polymorphisms of protein transporters can alter the pharmacokinetics and pharmacodynamics of several substrate drugs including antiretrovirals (ARVs). The polymorphisms of ABCB1 and SLCO1B1 have been investigated in Caucasian and some of Asian populations. However, the information of these single nucleotide polymorphisms (SNPs) in Thai population are limited.
Objective : The aim of this study was to determine the frequencies of the variant genotype and allele of ABCB1 and SLCO1B1 in Thai HIV-infected patients and to compare with the frequencies obtained from other populations.
Methods : Three SNPs: ABCB1 3435C>T, ABCB1 2677G>T and SLCO1B1 521T>C were identified by Taqman allelic discrimination assays using real time polymerase chain reaction system. Chi-square test was performed to compare the distributions of observed genotypes with expected genotypes according to Hardy-Weinberg equilibrium and to compare the proportions of allele frequencies between our population and other ethnic populations.
Results : A total of 521 patients were included in this study. The homozygous variant genotypes were 22.50%, 29.75%, and 3.84% for ABCB1 3435TT, ABCB1 2677TT and SLCO1B1 521CC, respectively. The allele frequencies of ABCB1 3435C>T, ABCB1 2677G>T and SLCO1B1 521T>C were 47.70%, 51.06%, and 11.90%, respectively. The prevalence of ABCB1 2677G>T was similar to other Asian populations, but the prevalence of ABCB1 3435C>T was different from the Chinese and the Korean populations. In addition, higher variant allele frequencies of ABCB1 3435T, ABCB1 2677T and SLCO1B1 521C were observed in Thais compared to African Americans.
Conclusion : We found that gene polymorphisms of ABCB1 and SLCO1B1 were frequent in Thai HIV-infected patients. These results could provide an evidence for future clinical studies regarding the variability in treatment responses and a risk of adverse effects of ARVs which are substrate of these transporters in Thai population.
Downloads
References
Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009;26:2039-54. https://doi.org/10.1007/s11095-009-9924-0
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin Pharmacokinet 2015;54:709-35. https://doi.org/10.1007/s40262-015-0267-1
Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013;28:4-18. https://doi.org/10.2133/dmpk.DMPK-12-RV-099
Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16:1501-11. https://doi.org/10.1681/ASN.2004100882
Choi JR, Kim JO, Kang DR, Shin J-Y, Zhang XH, Oh JE, et al. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat 2015;47:509-17. https://doi.org/10.4143/crt.2014.012
Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs. Clin Pharmacokinet 2017;56:355-69. https://doi.org/10.1007/s40262-016-0456-6
Barco EÁ, Rodri guez Nóvoa S. The pharmacogenetics of HIV treatment: a practical clinical approach. J Pharmacogenomics Pharmacoproteomics 2013;4:116.
Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Re. 2011; 63:157-81.
https://doi.org/10.1124/pr.110.002857
Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 2017;83:1176-84.
https://doi.org/10.1111/bcp.13207
Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmgenomics Pers Med 2012;5:1-17.
https://doi.org/10.2147/PGPM.S15303
Chaikan A, Chierakul N, Saguenwong N, Chuchuttaworn C, Owen A, Dickinson L, et al. Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. J Int AIDS Soc 2008;11:P237. https://doi.org/10.1186/1758-2652-11-S1-P237
Avihingsanon A, Tongkobpetch S, Kerr SJ, Punyawudho B, Suphapeetiporn K, Gorowara M, et al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr 2015;69:e36-e7. https://doi.org/10.1097/QAI.0000000000000540
Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIVinfected patients. Ther Drug Monit 2010;32: 573-8. https://doi.org/10.1097/FTD.0b013e3181ea953c
Park WB, Choe PG, Song K-H, Jeon JH, Park SW, Kim HB, et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDPglucuronosyltransferase 1A1* 28 allele frequency. Clin Infect Dis 2010;51:101-6. https://doi.org/10.1086/653427
Tsai MS, Chang SY, Lin SW, Kuo CH, Sun HY, Wu BR, et al. Treatment response to unboostedatazanavir in combination with tenofovirdisoproxilfumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. J MicrobiolImmunol Infect 2017;50:789-97.
https://doi.org/10.1016/j.jmii.2015.12.012
Benish RL, Rodriguez B, Zimmerman PA, Mehlotra RK. Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIVnegative populations. Infect Genet Evol 2010;10:60-7. https://doi.org/10.1016/j.meegid.2009.09.018
Zhang X, Tierney C, Albrecht M, Demeter LM, Morse G, DiFrancesco R, et al. Discordant associations between SLCO1B1 521T->C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Ther Drug Monit 2013;35: 209-16.
https://doi.org/10.1097/FTD.0b013e318280d0ad
Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit 2011; 33:417-24.
https://doi.org/10.1097/FTD.0b013e318225384f
Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, et al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet 2016; 61:119-27.
https://doi.org/10.1038/jhg.2015.115
Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010;31:22-35.
https://doi.org/10.1016/j.tips.2009.10.001
Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol 2007;64:353-62. https://doi.org/10.1111/j.1365-2125.2007.02903.x
Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006;42:441-9. https://doi.org/10.1097/01.qai.0000225013.53568.69
Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbé L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005;192:1931-42. https://doi.org/10.1086/497610
Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010;202: 717-22. https://doi.org/10.1086/655470
Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359: 30-6. https://doi.org/10.1016/S0140-6736(02)07276-8
Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010;20:112-20.
https://doi.org/10.1097/FPC.0b013e328335b02d
Kohlrausch FB, de Cassia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010;69:95-8. https://doi.org/10.1111/j.1365-2125.2009.03551.x
Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011;21:152-61.
https://doi.org/10.1097/FPC.0b013e3283385a1c
Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS, et al. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit 2005;27:531-5. https://doi.org/10.1097/01.ftd.0000164293.75854.11
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chulalongkorn Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
